Doctor Adam Ioannou

Back

Doctor Adam Ioannou

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

Presentations

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Event: Heart Failure 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Access

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Event: Heart Failure 2023

Topic: Imaging

Session: Cardiac amyloidosis from epidemiology to treatment

Access

Tracking multi-organ treatment response in systemic AL amyloidosis with cardiac magnetic resonance derived extracellular volume mapping

Event: EACVI 2023

Topic: Myocardial Disease

Session: Young Investigators Award Clinical Cardiology

Access

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Event: EACVI 2023

Topic: Myocardial Disease

Session: Dechiphering the phenotypes and dynamics of cardiomyopathies under the light of multi-modality imaging

Access

Automated analysis of echocardiograms at diagnosis is able to predict prognosis in ATTR cardiomyopathy

Event: EACVI 2023

Topic: Myocardial Disease

Session: Cardiac Amyloidosis 1

Access

Myocardial ischaemia in cardiac amyloidosis: a change of perspective

Event: ESC Congress 2022

Topic: Infiltrative Myocardial Disease

Session: A focus on cardiac amyloidosis

Access

Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis

Event: ESC Congress 2022

Topic: Infiltrative Myocardial Disease

Session: Cardiac amyloidosis

Access

Changes in referral pathway and phenotypic status of patients diagnosed with ATTR cardiac amyloidosis during the past 20 years

Event: ESC Congress 2022

Topic: Infiltrative Myocardial Disease

Session: Cardiac amyloidosis: steps ahead

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Adam Ioannou Follow

Contributor content

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Tracking multi-organ treatment response in systemic AL amyloidosis with cardiac magnetic resonance derived extracellular volume mapping

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Automated analysis of echocardiograms at diagnosis is able to predict prognosis in ATTR cardiomyopathy

Myocardial ischaemia in cardiac amyloidosis: a change of perspective

Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis

Changes in referral pathway and phenotypic status of patients diagnosed with ATTR cardiac amyloidosis during the past 20 years

ESC 365 is supported by

Doctor Adam Ioannou